AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
275.88B
Market cap275.88B
Price-Earnings ratio
26.67
Price-Earnings ratio26.67
Dividend yield
1.76%
Dividend yield1.76%
Average volume
1.97M
Average volume1.97M
High today
$180.44
High today$180.44
Low today
$177.65
Low today$177.65
Open price
$178.93
Open price$178.93
Volume
1.87M
Volume1.87M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$137.23
52 Week low$137.23

Stock Snapshot

AstraZeneca(AZN) stock is priced at $179.48, giving the company a market capitalization of 275.88B. It carries a P/E multiple of 26.67 and pays a dividend yield of 1.76%.

On 2026-06-18, AstraZeneca(AZN) stock traded between a low of $177.65 and a high of $180.44. Shares are currently priced at $179.48, which is +1.0% above the low and -0.5% below the high.

AstraZeneca(AZN) shares are trading with a volume of 1.87M, against a daily average of 1.97M.

In the last year, AstraZeneca(AZN) shares hit a 52-week high of $212.71 and a 52-week low of $137.23.

In the last year, AstraZeneca(AZN) shares hit a 52-week high of $212.71 and a 52-week low of $137.23.

AZN News

TipRanks 16h
AstraZeneca Advances Fixed-Dose Cholesterol Combo With New Phase I Bioavailability Data

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium fo...

Zacks 2d
FDA Accepts AstraZeneca's Filing for Expanded Use of Ultomiris - Zacks Investment Research

...

FDA Accepts AstraZeneca's Filing for Expanded Use of Ultomiris - Zacks Investment Research
TipRanks 3d
AstraZeneca’s sBLA for Ultomiris granted Priority Review by U.S. FDA

Alexion, AstraZeneca (AZN) Rare Disease’s supplemental Biologics License Application, sBLA, for Ultomiris has been accepted and granted Priority Review by the U...

Analyst ratings

83%

of 29 ratings
Buy
82.8%
Hold
10.3%
Sell
6.9%

More AZN News

Nasdaq 5d
AstraZeneca : FDA Approves Truqap Combination For PTEN-Deficient Metastatic Prostate Cancer

(RTTNews) - AstraZeneca's (AZN,AZN.L,ZEG.DE,AZN.ST) Truqap (capivasertib), in combination with abiraterone and prednisone, has been approved in the US as the fi...

AstraZeneca : FDA Approves Truqap Combination For PTEN-Deficient Metastatic Prostate Cancer
Seeking Alpha 6d
AstraZeneca gets FDA label expansion for Truqap in prostate cancer

AstraZeneca (AZN) on Friday announced that the U.S. Food and Drug Administration approved a label expansion for its anti-tumor agent Truqap (capivasertib) as pa...

AstraZeneca gets FDA label expansion for Truqap in prostate cancer
TipRanks 6d
AstraZeneca’s AZD1390 ADME Study Lays Groundwork for Future Oncology Upside

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca is preparing a new early-stage trial that looks at how its drug AZD13...

TipRanks 6d
AstraZeneca’s GRANITE Study Puts Airsupra’s Real‑World Edge Over Albuterol to the Test

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The GRANITE study, formally titled “Airsupra Effectiveness in the Real World,” reviews...

Nasdaq 6d
Astrazeneca Outperforms Broader Market: What You Need to Know

Astrazeneca (AZN) ended the recent trading session at $75.57, demonstrating a +1.79% swing from the preceding day's closing price. This change outpaced the S&P...

Astrazeneca Outperforms Broader Market: What You Need to Know

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.